



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Aprotinin

Cat. No.:	HY-P0017
CAS No.:	9087-70-1
Molecular Formula:	C ₂₈₄ H ₄₃₂ N ₈₄ O ₇₉ S ₇
Molecular Weight:	6511
Sequence:	Arg-Pro-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro-Cys-Lys-Ala-Arg-Ile-Ile-Arg-Tyr-Phe-Tyr-Asn-Ala-Lys-Ala-Gly-Leu-Cys-Gln-Thr-Phe-Val-Tyr-Gly-Gly-Cys-Arg-Ala-Lys-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys-Met-Arg-Thr-Cys-Gly-Gly-Ala(Disulfide bridge: Cys5-Cys55,Cys14-Cys38,Cys30-Cys51)
Sequence Shortening:	RPDFCLEPPYTGPKARIIRYFYNAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA(Disulfide bridge: Cys5-Cys55,Cys14-Cys38,Cys30-Cys51)
Target:	Influenza Virus; Ser/Thr Protease
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

RPDFCLEPPYTGPKARIIRYFYNAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA(Disulfide bridge: Cys5-Cys55,Cys14-Cys38,Cys30-Cys51)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (15.36 mM; Need ultrasonic)																							
	DMSO : 66.67 mg/mL (10.24 mM; ultrasonic and adjust pH to 3 with HCl)																							
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>Preparing Stock Solutions</td> <td></td> <td></td> <td></td> </tr> <tr> <td>1 mM</td> <td>0.1536 mL</td> <td>0.7679 mL</td> <td>1.5359 mL</td> </tr> <tr> <td>5 mM</td> <td>0.0307 mL</td> <td>0.1536 mL</td> <td>0.3072 mL</td> </tr> <tr> <td>10 mM</td> <td>0.0154 mL</td> <td>0.0768 mL</td> <td>0.1536 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass			1 mg	5 mg	10 mg	Preparing Stock Solutions				1 mM	0.1536 mL	0.7679 mL	1.5359 mL	5 mM	0.0307 mL	0.1536 mL	0.3072 mL	10 mM	0.0154 mL	0.0768 mL	0.1536 mL
	Solvent Concentration		Mass																					
1 mg		5 mg	10 mg																					
Preparing Stock Solutions																								
1 mM	0.1536 mL	0.7679 mL	1.5359 mL																					
5 mM	0.0307 mL	0.1536 mL	0.3072 mL																					
10 mM	0.0154 mL	0.0768 mL	0.1536 mL																					
Please refer to the solubility information to select the appropriate solvent.																								
In Vivo	1. Add each solvent one by one: PBS Solubility: 50 mg/mL (7.68 mM); Clear solution; Need ultrasonic																							

BIOLOGICAL ACTIVITY

Description	Aprotinin is a bovine pancreatic trypsin inhibitor (BPTI) inhibitor which inhibits trypsin and chymotrypsin with K _s of 0.06 pM and 9 nM, respectively.
IC₅₀ & Target	Ki: 0.06 pM (Trypsin), 9 nM (Chymotrypsin) ^[1]
In Vitro	Aprotinin, a serine protease inhibitor isolated from bovine lung, is a complex protease inhibitor that is an antifibrinolytic, inhibits contact activation, and decreases the inflammatory response to cardiopulmonary bypass ^[2] . Aprotinin inhibits

trypsin (bovine, $K_i = 0.06 \text{ pM}$), chymotrypsin (bovine, $K_i = 9 \text{ nM}$), plasmin (human, 0.23 nM)^[1]. Aprotinin is also a competitive protein inhibitor of NOS activity. It inhibits NOS-I and NOS-II with K_i values of $50 \text{ }\mu\text{M}$ and $78 \text{ }\mu\text{M}$, respectively^[3]. Aprotinin significantly inhibits fibrinolysis with an IC_{50} of $0.16 \pm 0.05 \text{ }\mu\text{M}$ ^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

High dose aprotinin can reduce blood loss and transfusion requirements associated with primary cardiac procedures such as coronary artery bypass graft (CABG) or heart valve replacement surgery^[5]. Aprotinin inhibits thrombus formation in a dose-dependent manner. Aprotinin at a dose of 1.5 mg kg^{-1} (bolus) and $3 \text{ mg kg}^{-1} \text{ h}^{-1}$ infusion (maintenance infusion) causes a tendency towards a reduction in bleeding time. Aprotinin significantly reduces the bleeding time starting at a dose of 3 mg kg^{-1} bolus plus $6 \text{ mg kg}^{-1} \text{ h}^{-1}$ showing a reduction of approximately $84\% \pm 2.9\%$. At the highest dose of 5 mg kg^{-1} and $10 \text{ mg kg}^{-1} \text{ h}^{-1}$, the strongest effects are observed^[4]. Aprotinin may affect tumor necrosis factor-alpha (TNF) levels. Soluble TNFR1 levels are significantly increased following I/R in the aprotinin treated wild type mice and not detected in all TNFR1null mice^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration^{[4][6]}

Rats: Male Wistar rats (180-220 g) are used in the study. Aprotinin is dissolved in physiological saline. Aprotinin is administered by bolus injection followed by a maintenance infusion. The doses given are 1.5 mg kg^{-1} and $3 \text{ mg kg}^{-1} \text{ h}^{-1}$, 3 mg kg^{-1} and $6 \text{ mg kg}^{-1} \text{ h}^{-1}$ up to 5 mg kg^{-1} and $10 \text{ mg kg}^{-1} \text{ h}^{-1}$. Plasma concentrations for the two agents are assessed by pharmacokinetic studies in rats^[4].

Mice: An intact mouse model of ischemia/reperfusion (30 min-I/60 min-R) is used and left ventricular peak + dP/dt is measured in wild type mice (WT, C57BL/6; n=10), WT mice with aprotinin (4 mL/kg ; n=10), transgenic mice devoid of the TNFR1 (TNFR1null; n=10), and TNFR1null with aprotinin (n=10)^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2023 Jul 26;14(1):4487.
- Nat Commun. 2023 May 2;14(1):2523.
- Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2208211119.
- Cell Rep. 2021 Nov 2;37(5):109931.
- Am J Physiol Cell Physiol. 2017 Dec 1;313(6):C632-C643.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Fritz H, et al. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. *Arzneimittelforschung*. 1983;33(4):479-94.
- [2]. Levy JH, et al. Efficacy and safety of aprotinin in cardiac surgery. *Orthopedics*. 2004 Jun;27(6 Suppl):s659-62.
- [3]. Venturini G, et al. Aprotinin, the first competitive protein inhibitor of NOS activity. *Biochem Biophys Res Commun*. 1998 Aug 10;249(1):263-5
- [4]. Sperzel M, et al. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. *J Thromb Haemost*. 2007 Oct;5(10):2113-8. Epub 2007 Jul 31.
- [5]. Davis R, et al. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. *Drugs*. 1995 Jun;49(6):954-83.

[6]. Sabbagh MJ, et al. Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I. J Cardiovasc Pharmacol. 2008 Oct;52(4):355-62.

[7]. Levy JH, et al. Efficacy and safety of aprotinin in cardiac surgery. Orthopedics. 2004 Jun;27(6 Suppl):s659-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA